Lord Strasburger

The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) have dedicated funding to research into treatment options, clinical trials, and to understanding the underlying mechanisms of long COVID. The overall Government investment in long COVID research is over £57 million. Government research funders welcome applications for funding for long COVID research.

Of the research studies identified in the answer for HL5426, four are ongoing and have expected spend in this financial year, namely: STIMULATE-ICP; PHOSP-COVID; Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue; and Online cognitive training for people with cognitive impairment following SARS-CoV-2 infection. The total budget for these studies is over £15 million, but spend in this financial year is not yet confirmed, as it depends on the progress of the studies.

No specific assessment has been made of the progress of United Kingdom-based researchers on finding methods to treat the symptoms of long COVID. The UK has a strong track record of developing and evaluating new treatments for COVID-19 through randomised control trials. In November 2020, the NIHR and UKRI launched their first call for research proposals on long COVID and subsequently funded the treatments for long COVID. In 2021, the NIHR funded the STIMULATE-ICP study as the largest trial for long COVID treatments at the time. This study is still ongoing, and emerging findings will be shared with the National Institute for Health and Care Excellence. The NIHR Innovation Observatory has undertaken a rapid horizon scan to identify repurposed medicines in clinical development for the treatment of myalgic encephalomyelitis, also known as chronic fatigue syndrome, as well as related conditions such as long COVID and fibromyalgia. The horizon scan focused on medicines with a UK licence that are in phase two or three clinical trials, with trial registration dates from 2020 onwards.

Unfortunately, no study globally has identified a cure for long COVID. The REGAIN study became the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high quality evidence confirming the sustained clinical benefit and lack of harm from rehabilitation programmes for long COVID. The NIHR provided £1.5 million towards this trial, which combined exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.

The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) have dedicated funding to research into treatment options, clinical trials, and to understanding the underlying mechanisms of long COVID. The overall Government investment in long COVID research is over £57 million. Government research funders welcome applications for funding for long COVID research.

Of the research studies identified in the answer for HL5426, four are ongoing and have expected spend in this financial year, namely: STIMULATE-ICP; PHOSP-COVID; Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue; and Online cognitive training for people with cognitive impairment following SARS-CoV-2 infection. The total budget for these studies is over £15 million, but spend in this financial year is not yet confirmed, as it depends on the progress of the studies.

No specific assessment has been made of the progress of United Kingdom-based researchers on finding methods to treat the symptoms of long COVID. The UK has a strong track record of developing and evaluating new treatments for COVID-19 through randomised control trials. In November 2020, the NIHR and UKRI launched their first call for research proposals on long COVID and subsequently funded the treatments for long COVID. In 2021, the NIHR funded the STIMULATE-ICP study as the largest trial for long COVID treatments at the time. This study is still ongoing, and emerging findings will be shared with the National Institute for Health and Care Excellence. The NIHR Innovation Observatory has undertaken a rapid horizon scan to identify repurposed medicines in clinical development for the treatment of myalgic encephalomyelitis, also known as chronic fatigue syndrome, as well as related conditions such as long COVID and fibromyalgia. The horizon scan focused on medicines with a UK licence that are in phase two or three clinical trials, with trial registration dates from 2020 onwards.

Unfortunately, no study globally has identified a cure for long COVID. The REGAIN study became the first randomised trial to show a benefit from rehabilitation for people with long COVID, and the first high quality evidence confirming the sustained clinical benefit and lack of harm from rehabilitation programmes for long COVID. The NIHR provided £1.5 million towards this trial, which combined exercise with behavioural support, to measure their effects on symptoms, health, and other outcomes.

The National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI) have dedicated funding to research into treatment options, clinical trials, and to understanding the underlying mechanisms of long COVID. This investment spans both infrastructure supported projects and programme awards.

The total funding for the research studies, which include at least one element on treatments, is over £16.2 million. We have provided the overall figures of investment into the relevant studies, although not all funding would have been directly spent on treatments or clinical trials, which are as follows:

• £6.97 million for the STIMULATE-ICP trial, which is a large-scale, pragmatic, multi-centre, cluster randomised trial evaluating an integrated care pathway with a nested, phase three, open label, adaptive platform randomised drug trial in individuals with long COVID;
• £3.7 million for the HEAL-COVID platform trial, which assesses treatments to reduce complications in hospitalised COVID-19 patients, with implications for preventing long COVID;
• £1.1 million for the ReDIRECT trial, which is a randomised controlled trial evaluating a remotely delivered diet intervention for people with long COVID and excess weight;
• £1.08 million for the LISTEN trial, which is a randomised controlled trial based on a personalised self-management intervention for people with long COVID, where the intervention includes co-designed digital and paper resources and training for healthcare professionals;
• £1.83 million for the Therapies for Long COVID (TLC) study, which included a feasibility trial of pacing interventions for long COVID, which aimed to co-produce a feasibility study of non-pharmacological interventions to support people with long COVID. This was part of the TLC study, and the figure refers to the TLC study overall;
• £8.8 million for the PHOSP-I Trial, which is a phase two, double-blind, randomised, placebo-controlled trial investigating the effect of tocilizumab on the quality of life in adults with long COVID and persistent inflammation after hospitalisation;
• £1.29 million for the CICERO trial, which is a randomised controlled trial using telehealth-delivered cognitive rehabilitation for people with cognitive impairment as part of long COVID;
• £335,000 for online cognitive training for people with cognitive impairment following SARS-CoV-2 infection, and which is a randomised controlled clinical trial looking to assess whether online brain training games can help people with cognitive impairment following SARS-CoV-2 infection;
• £459,000 for Using Activity Tracking and Just-In-Time Messaging to Improve Adaptive Pacing, which is a pragmatic randomised controlled trial to evaluate mobile technology as a tool for improving adaptive pacing among individuals with long COVID;
• £640,000 for Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue, which aims to establish whether self-administered non-invasive transcutaneous vagus nerve stimulation can reduce symptoms of post-COVID fatigue in adults with long COVID; and
• £758,000 from UKRI via Innovate UK into two projects that focus on developing innovative digital therapeutics to support treatment options for long COVID patients.

The most recent data from the Winter Coronavirus (COVID-19) Infection Study, a joint study carried out by the Office for National Statistics (ONS) and the UK Health Security Agency, shows that, for the period 6 February 2024 to 7 March 2024, an estimated 1.8 million people, or 3.3% of the population, in private households in England, self-reported experiencing long COVID symptoms more than four weeks after a COVID-19 infection. The following table shows a breakdown of duration:

No estimate has been made of the rate at which prevalence of long COVID is currently increasing or decreasing in England. The ONS does not regularly collect this data.

No estimate has been made of the effect of long COVID on the economy in each year from 2020 to 2024, including the effect with respect to those affected by long COVID of their economic inactivity, the diminution in their quality of life, their lost income, the cost of informal caregiving for them, and their extra healthcare costs.

The most recent data from the infection study shows that for those who self-report long COVID of any duration, in England and Scotland, who are aged between 16 and 64 years old and are not in education are less likely to be employed or self-employed compared with those who have not reported long COVID.

On 18 December 2020, NHS England had put in place 69 dedicated clinics across the country. As of 1 April 2024, there were over 90 adult post-COVID services across England along with an additional 10 children and young people’s hubs.

The most recent data from the Winter Coronavirus (COVID-19) Infection Study, a joint study carried out by the Office for National Statistics (ONS) and the UK Health Security Agency, shows that, for the period 6 February 2024 to 7 March 2024, an estimated 1.8 million people, or 3.3% of the population, in private households in England, self-reported experiencing long COVID symptoms more than four weeks after a COVID-19 infection. The following table shows a breakdown of duration:

No estimate has been made of the rate at which prevalence of long COVID is currently increasing or decreasing in England. The ONS does not regularly collect this data.

No estimate has been made of the effect of long COVID on the economy in each year from 2020 to 2024, including the effect with respect to those affected by long COVID of their economic inactivity, the diminution in their quality of life, their lost income, the cost of informal caregiving for them, and their extra healthcare costs.

The most recent data from the infection study shows that for those who self-report long COVID of any duration, in England and Scotland, who are aged between 16 and 64 years old and are not in education are less likely to be employed or self-employed compared with those who have not reported long COVID.

On 18 December 2020, NHS England had put in place 69 dedicated clinics across the country. As of 1 April 2024, there were over 90 adult post-COVID services across England along with an additional 10 children and young people’s hubs.

Details of the pilot schemes carried out by South Wales Police will be set out in due course as part of a wider publication by the Home Office on its approach to the use of live facial recognition technology.